The stock of Aequus Pharmaceuticals Inc (CVE:AQS) gapped down by $0.005 today and has $0.24 target or 10.00% below today’s $0.27 share price. The 6 months technical chart setup indicates high risk for the $14.62 million company. The gap down was reported on Nov, 15 by Barchart.com. If the $0.24 price target is reached, the company will be worth $1.46M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. About 49,500 shares traded hands. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since October 16, 2016 and is uptrending. It has outperformed by 2.07% the S&P500.
More notable recent Aequus Pharmaceuticals Inc (CVE:AQS) news were published by: Marketwired.com which released: “Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing” on September 06, 2016, also Marketwired.com with their article: “Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director” published on March 17, 2015, Marketwired.com published: “Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN(TM) in Canada” on April 28, 2016. More interesting news about Aequus Pharmaceuticals Inc (CVE:AQS) were released by: Marketwired.com and their article: “Aequus Closes Financing for Gross Proceeds of C$2743920” published on September 13, 2016 as well as Business.Financialpost.com‘s news article titled: “Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug …” with publication date: May 03, 2016.
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical firm focused on developing and commercializing products. The company has a market cap of $14.62 million. The Firm operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. It currently has negative earnings. The Company’s products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release , which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.